金十数据6月13日讯，国家卫生健康委等14部门发布《关于印发2025年纠正医药购销领域和医疗服务中 不正之风工作要点》，其中提到，重点打击网络"医托"、违规发布医药广告，以及假借医学科普或会议 活动等"引流""带货"、伪造编造变造在职或离退休行业人员视频营销牟利等不法行为。紧盯定点医疗机 构、定点零售药店、职业骗保人，严厉打击欺诈骗保和整治违规使用医保基金行为，用好多部门联合惩 戒机制。 （央视新闻） 纠正医药购销领域和医疗服务中不正之风 14部委联合发文 ...

Core Viewpoint - The Sichuan Provincial Government has issued an opinion to support Chengdu in enhancing its core functions and accelerating high-quality development, aiming to establish it as a western economic center, technology innovation center, international exchange center, and a national advanced manufacturing base [1][2]. Group 1: Economic Development - The opinion outlines 15 specific measures to enhance Chengdu's economic growth, focusing on becoming a western economic center by expanding domestic demand and improving resource allocation capabilities [2]. - Chengdu is encouraged to develop into an international consumption center and to co-build a western financial center with Mianyang [2]. Group 2: Technological Innovation - The opinion emphasizes the need for Chengdu to strengthen its technological innovation capabilities, enhance the conversion of scientific achievements, and deepen reforms in the technology system [2][3]. - Chengdu will implement breakthrough actions in frontier technologies such as artificial intelligence, aerospace, biomanufacturing, and clean energy [2]. Group 3: International Exchange - To establish Chengdu as a western international exchange center, the opinion supports the development of a comprehensive international transportation hub and the strengthening of high-level open platforms [2]. - Specific initiatives include the construction of the Tianfu International Airport Phase II and the enhancement of the international flight network [2]. Group 4: Advanced Manufacturing - The opinion aims to support Chengdu in building a world-class advanced manufacturing cluster and nurturing emerging and future industries [3]. - Chengdu will establish new provincial development zones in the Tianfu New Area and the Eastern New Area, and develop a world-class high-tech industrial park [3].

Core Points - The second "Belt and Road" Technology Exchange Conference concluded with a focus on building a technology innovation community, featuring over 38 specialized activities and participation from more than 6,000 guests from over 100 countries and international organizations [1][2] - The conference emphasized the importance of open cooperation and shared experiences, highlighting the collaborative efforts in technology innovation action plans among participating countries since the Belt and Road Initiative was proposed over a decade ago [1] - A declaration titled "Chengdu Declaration on Building a Technology Innovation Community along the Belt and Road" was released, calling for deeper technological cooperation and receiving enthusiastic responses from participating countries [1] Group 1 - The conference deepened technological exchange and cooperation, establishing mechanisms for the Belt and Road Technology Exchange Conference and Ministerial Meetings, and launching initiatives such as the "Double Thousand" plan for the Chengdu-Chongqing region [2] - The conference initiated the construction of the Chengdu-Chongqing International Technology Transfer Center and organized various technology transfer activities, enhancing industry-technology connections [2] - A total of 28 bilateral government technology cooperation documents were signed, and over 30 bilateral ministerial meetings were held, expanding the international technology cooperation network [2] Group 2 - The third "Belt and Road" Technology Exchange Conference is scheduled to be held in Chongqing in 2027 [3]

Core Viewpoint - The Hong Kong innovative drug sector has achieved a 78% increase as of June 6, 2025, marking the highest half-year growth since 2018, driven by multiple factors including domestic drug approvals and supportive national policies [1][2]. Group 1: 1H25 Review - As of June 6, 2025, the MSCI China Pharmaceutical Index and the Hang Seng Biotechnology Index have risen by 31% and 48% respectively, significantly outperforming the MSCI China Index (up 16%) and the Hang Seng Index (up 19%) [2]. - The innovative drug sector has seen the best performance with a 62% increase, while the pharmaceutical distribution sector has declined by 8% [2]. - The outperformance of the pharmaceutical sector is attributed to its immunity to the "tariff war," continuous improvement in fundamentals, and historically low valuations attracting new capital [2]. Group 2: 2H25 Outlook - The pharmaceutical sector's fundamentals are expected to improve further in 2H25 due to anticipated overseas licensing of domestic innovative drugs, supportive national policies, and rapid growth in innovative drug sales [3]. - The innovative drug sector is recommended as a top choice, particularly companies with strong R&D capabilities and significant commercial potential, such as Innovent Biologics (01801) and BeiGene (06160) [3]. - Innovent Biologics is positioned well with upcoming approvals for key drugs, while BeiGene has multiple catalysts expected in the second half of the year [3]. Group 3: Other Sectors - The medical device sector is expected to benefit from policy-driven demand for high-value consumables and equipment upgrades, with companies like Aikang Medical (01789) and Mindray Medical (300760.SZ) recommended for attention [4]. - The CXO sector shows signs of recovery in new order growth, with companies like WuXi AppTec (02269) and WuXi Biologics (02359) highlighted for their growth potential [4]. - The medical services sector is viewed positively, particularly in traditional Chinese medicine and ophthalmology services [5].

Group 1 - The conference focused on supporting the high-quality development of strategic emerging industries and future industries in Beijing, with the establishment of specialized committees for artificial intelligence, healthcare, embodied intelligence, and new energy materials [1][2] - The Vice Chairman of the All-China Federation of Industry and Commerce emphasized the importance of integrating technological and industrial innovation, and creating a collaborative system to support the high-quality development of the private economy in Beijing [1] - The Chairman of Beijing Municipal Political Consultative Conference highlighted the need to leverage the resources of the Federation to promote the coordinated development of industrial chains and financial systems, and to enhance innovation-driven mechanisms [1][2] Group 2 - The Beijing Federation of Industry and Commerce aims to implement four major projects: ideological guidance, mutual promotion, problem-solving for enterprises, and empowerment to enhance the integration of emerging and future industries [2] - The Federation will actively seek funding, projects, talent, and support for activities to create a collaborative effort in supporting services for industries [2]

Core Viewpoint - The initiative to bring traditional Chinese medicine (TCM) into universities aims to address students' health issues and promote wellness through innovative outreach methods [2][4]. Group 1: TCM Outreach and Engagement - TCM experts are visiting multiple universities in Shanghai to provide free consultations and health advice to students and faculty [1][2]. - The initiative includes a mobile TCM cultural promotion vehicle that offers herbal teas and educates students about TCM principles [1][4]. - The approach is designed to resonate with younger audiences, moving away from traditional didactic methods to more engaging formats [2]. Group 2: Health Issues Addressed - Common health concerns among students include anxiety, sleep problems, and menstrual discomfort, often exacerbated by stress and lifestyle choices [2][3]. - TCM practitioners are teaching students techniques to alleviate these issues, such as acupressure for eye strain and dietary recommendations for menstrual health [3][4]. - The emphasis is on developing healthy habits early in life to prevent future health problems [3]. Group 3: Student Reception and Feedback - Students have shown a strong interest in TCM, with many expressing a desire to learn more about its benefits and practices [3][4]. - Positive testimonials highlight the effectiveness of TCM treatments, such as acupuncture for pain relief and herbal remedies for skin conditions [3][4]. - The mobile TCM promotion vehicle has garnered significant attention, indicating a high level of engagement from the student body [4].

Group 1 - The market is witnessing a rapid increase in new fund issuance, with several funds ending their fundraising periods early to seize investment opportunities [1][2] - On June 12, multiple equity funds announced early closure of their fundraising, indicating strong demand and optimism among fund companies [1] - The first batch of new floating management fee funds has already exceeded 8 billion yuan in issuance scale, reflecting a shift in fund management strategies [1] Group 2 - New funds are being established quickly, with some having fundraising periods as short as 2 days, highlighting a focus on swift market entry [2] - Fund managers are actively purchasing their own funds, demonstrating confidence in the market's long-term stability and growth potential [2] - Economic resilience and potential in China are expected to support market valuation recovery, with sectors like AI, high-end manufacturing, and biomedicine showing promising developments [3]

以下文章来源于21新健康 ，作者李佳英 21新健康 . 21世纪传媒 · 公众号矩阵成员。 编 辑丨季媛媛 图 源丨图虫 原料药领域又现垄断案。 近日，联环药业称收到天津市场监管委员会的《行政处罚决定书》， 因操纵地塞米松磷酸钠 原料药价格，被罚没6103.82万元，占其2024年净利润的72.53% 。而就在近期，津药药业、 仙琚制药也因同一垄断行为被重罚， 三家企业罚没总额高达3.26亿元 。 涉事药企表示将立即组织整改，终止相关不当行为，并积极主动向客户寄送《调价通知函》 。 这场风暴涉及的地塞米松，曾被列入《新型冠状病毒感染的肺炎诊疗方案》。然而，根据公开 信息， 其价格曾从0.35元/支暴涨至98.76元/支，涨幅高达282倍 。 相 关 处 罚 决 定 书 披 露 了 背 后 的 垄 断 手 法 ： 多 家 药 企 及 相 关 人 员 不 仅 达 成 " 停 止 价 格竞争、共同涨价"的口头协议，还通过商业公司"兜底采购"确保垄断实施。 "津药药业、联环药业、西安国康瑞金和仙琚制药这四家企业的行为属于典型的串通涨价。"北 京市京都律师事务所反垄断部主管合伙人、耀时跨境合规研究院研究员金毅向21世纪 ...

Group 1 - The event "China-Africa Traditional Medicine Trade Cooperation" was held in Changsha, focusing on building a new ecosystem for collaborative development in traditional medicine between China and Africa [1] - Traditional Chinese medicine (TCM) has been shared with 196 countries and regions, gaining acceptance for its unique advantages in disease prevention, treatment, and rehabilitation [1] - China has signed memorandums of understanding for traditional medicine cooperation with 10 countries, including Algeria and Ghana, and established TCM centers in Zimbabwe, Comoros, Morocco, and Mauritius [1] Group 2 - The Chinese government emphasizes the importance of traditional medicine cooperation with Africa, integrating it into the agenda of the 2024 China-Africa Cooperation Forum [1] - The event is a significant step in implementing the outcomes of the China-Africa Cooperation Forum, aimed at enhancing traditional medicine collaboration [1] - Zimbabwe's Minister of Health expressed the desire to collaborate with Chinese enterprises and research institutions to improve the production capacity of traditional medicine in Zimbabwe [2]

证券代码：301246 证券简称：宏源药业 答：您好，公司固态硫化物电解质已完成公斤级实验，正处 于工艺优化的开发阶段，没有量产供货。感谢您的关注！ 5、董秘，请问公司在固态电池方面，有何布局，目前进展如何？ 答：您好，公司固态硫化物电解质已完成公斤级实验，正处 于工艺优化的开发阶段，后续的相关进展或变化，公司将严格按 照相关规定及时履行披露义务。 感谢您的关注！ 湖北省宏源药业科技股份有限公司 投资者关系活动记录表 编号：2025-002 | | | □特定对象调研□分析师会议 | | --- | --- | --- | | 投资者关系活动 | □媒体采访□业绩说明会 | | | 类别 | □新闻发布会□路演活动 | | | | □现场参观 | | | | 年湖北辖区上市公司投资者网上集体接待日活动）  其他（2025 | | | 参与单位名称及 | 线上参与"2025 年湖北辖区上市公司投资者网上集体接待日活 | | | 人员姓名 | 动"的全体投资者 | | | 时间 | 2025 年 6 月 12 日 (周四) 下午 14:30~16:50 | | | 地点 | 全景网"投资者关系互动平台"（htt ...